← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Myosin Therapeutics Inc.
Jupiter, FL
$9,841,218
Total funding
5
Grants
Funding over time
peak $4.9M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,841,218 · 5
By mechanism
R44$6,925,301 · 3
R42$2,666,500 · 1
SB1$249,417 · 1
Investigators at Myosin Therapeutics Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Phase 0/I dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas$2,245,802
R44 · FY2025 · CA
Phase 0/1b Clinical Trial of Novel Therapeutic Agent MT-110 for the Reduction of Methamphetamine Use - Part 2$1,496,586
R44 · FY2025 · DA
MT-125 for the Therapeutic Treatment of Glioblastoma$1,348,593
R42 · FY2024 · CA
Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse$1,208,298
R44 · FY2023 · DA
Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse$1,208,298
R44 · FY2022 · DA
MT-125 for the Therapeutic Treatment of Glioblastoma$911,407
R42 · FY2025 · CA
Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse$440,888
R44 · FY2023 · DA
MT-125 for the Therapeutic Treatment of Glioblastoma$406,500
R42 · FY2023 · CA
Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse$325,429
R44 · FY2021 · DA
Development of drug product to support a Phase 0/1b dose escalation trial of MT-125 in recurrent high grade gliomas$249,417
SB1 · FY2025 · CA